Dr. Mou has nearly 20 years’industrial experiences in CMC development and manufacturing, global IND/BLA filing of mAb, ADC, mRNA, and viral vector based therapeutic and preventive medicine, especially in the field of immune-oncology and infectious diseases. She serves as an expert at IFPMA for the new Cell and Gene Therapies Discussion Group(CGTDG),and a member at Drug R&D Specialty Committee of PHIRDA.  Dr. Mou also has extensive experience in rapidly advancing projects into clinical stages in the fields of cell and gene therapy and rare diseases. She was responsible for the global supply chain management and commissioning of multiple new integrated development/manufacturing sites.

Previously, Dr. Mou served as Vice President of WuXi Biologics in Bioprocess Development and Production, and as the site head of WuXi Biologics Hangzhou Site, which she led to build from scratch and set up a team of nearly 1000 people as a global integration platform of microbial and viral product development and manufacturing.

At WuXi Biologics, Dr. Mou has served as Director of QC, Head of Global Project Management, Operation and Global Supply Chain, leading the project team to successfully complete clinical and commercial approval of innovative and biosimilar biological drugs in USA, Europe, Australia, Singapore, South Korea and China.

Before joining WuXi Biologics, Dr. Mou worked as the principal scientist and New Technology Group team leader, as well as the project manager of BioProcess Development at Merck, MSD USA, and a senior scientist and bioanalytical leader of BioTherapeutics Division at Pfizer, USA.

Dr. Mou obtained her Ph.D. in Chemistry and Chemical Biology at Rensselaer Polytechnic Institute and her bachelor's degree at Fudan University.